Filing Flows › Gilead Sciences (GILD) › Total Cell Therapy revenue
Gilead Sciences (GILD) Total Cell Therapy revenue by quarter
Gilead Sciences' Total Cell Therapy revenue was $355M in Q3 2026 (third quarter 2026), -15% from Q2 2026. Over the last 6 quarters it ranged from $355M (Q3 2026) to $485M (Q2 2025).
| Quarter | Total Cell Therapy revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $355M | -15% | -18% |
| Q2 2026 | $417M | +2% | -14% |
| Q1 2026 | $407M | -6% | -12% |
| Q3 2025 | $432M | -11% | — |
| Q2 2025 | $485M | +5% | — |
| Q1 2025 | $464M | — | — |
Q3 2026 at a glance
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Gilead Sciences' Total Cell Therapy revenue?
Gilead Sciences' Total Cell Therapy revenue was $355M in Q3 2026 (third quarter 2026), -15% from Q2 2026.
How has Gilead Sciences' Total Cell Therapy revenue changed?
Over the last 6 quarters it ranged from $355M (Q3 2026) to $485M (Q2 2025).